 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
COMMENTARY |
1 Professor and Associate Dean for Clinical Research and Public Policy, School of
Pharmacy, Virginia Commonwealth University-Medical College of Virginia Campus, 215 McGuire Hall,
1112 E. Clay St., PO Box 980533, Richmond, VA 23298, fax 804/628-3991, gmatzke@vcu.edu
* To whom correspondence should be addressed. E-mail: gmatzke{at}vcu.edu.
 |
Abstract |
|---|
The US healthcare system has been widely criticized by many and praised by others for many reasons that are not mutually exclusive. There is no doubt that, compared with our peer industrialized countries, the US ranks near the bottom in many of the benchmark criteria such as life expectancy, infant mortality, and mortality of the population that is amenable to health care. Despite these shortcomings, the US has been a major innovator in healthcare technology including the development of biological and pharmacological drugs. The shortcomings of our system are often focused on the fact that a significant portion of the population lacks access to these cutting-edge resources and therapies. In this commentary, the healthcare reform proposals that have been introduced in 2008-2009, with a focus on the 3 leading plans that have been put forward by the House of Representatives and Senate, are reviewed. The inclusion of pharmacist-delivered medication therapy management (MTM) as well as medication reconciliation (MedRec) is specifically stated in 2 of the 3 plans. Integrated care delivery models (ie, community health teams, or "medical homes") are also directed to provide MedRec and MTM during transitions of care. Finally, in the Senate Health, Education, Labor, and Pensions language, there is a directive that health insurers implement a payment schedule for MTM and care compliance. The many other ways in which each of these evolving reform proposals may impact pharmacists and the care they deliver to their communities are also highlighted.
Key Words: congressional proposals, healthcare insurance coverage, healthcare reform, loan forgiveness program, medical homes, medication therapy management, pharmacist impact.
Reprints: Dr. Matzke
Financial disclosure: None reported
 |
 |
 |
 |
 |
 |
 |
